Further purification of a CFU-S inhibitor: in vivo effects after cytosine arabinoside treatment
Wdzieczak-Bakala, J.; Guigon, M.; Lenfant, M.; Frindel, E.
Biomedicine and PharmacoTherapy 37(9-10): 467-471
1983
ISSN/ISBN: 0753-3322 PMID: 6689548 Document Number: 204548
This paper describes a large scale extraction procedure which allows the preparation of a stable CFU-S inhibitor from fetal calf bone marrow. The use of BioGel P-2 gels results in an increase of the specific activity of the inhibitor as well as in the yield of the preparation. When injected into mice, the inhibitory fraction (Ve/Vo 1.17-1.8) prevent CFU-S entry into cycle after cytosine arabinoside at a dose of 4 micrograms per mouse. When administered during lethal protocols of Ara-C treatment, it significantly increases the percentage of surviving animals. Thus, this low molecular weight factor (below 2,000 D), devoid of species-specificity, enhances the tolerance of animals to high doses of chemotherapy and might be of interest in cancer treatment.